merck post strong support robust keytruda
growth fade gener pressur
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim may
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
merck combin wide line-up high-margin drug
pipelin new drug ensur strong return invest
capit long term merck worst
patent cliff remov heighten gener
competit compani experienc past five year
sever year moder research develop
product merck drug develop strategi yield
merck new product mitig gener competit
offset recent major patent loss particular keytruda
cancer repres key blockbust multi-billion-dollar
potenti hold first-mov advantag one largest
cancer indic non-smal cell lung cancer also expect
new cancer drug combin propel merck overal
drug sale howev expect intens competit cancer
market sever competit drug like report import
clinic data headwind includ
gener competit notabl cardiovascular drug zetia
vytorin like creat drag overal growth
migrain safeti question end
sever year mix result merck product
improv compani shift toward area unmet
medic need owe side effect lack compel efficaci
merck experienc major setback cardiovascular diseas
drug anacetrapib tredapt rolofyllin tra along
develop osteoporosi drug odanacatib despit
setback merck solid success includ success
launch drug keytruda oncolog follow
success merck shift focu toward area unmet medic
need specialty-car area keytruda lead new
direct expect keytruda leadership non-smal cell lung
cancer key driver growth firm next
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
merck make pharmaceut product treat sever condit
number therapeut area includ cardiovascular diseas asthma
cancer infect within cancer firm immuno-oncolog platform
grow major contributor overal sale compani also
substanti vaccin busi treatment prevent hepat
pediatr diseas well hpv shingl addit merck sell
anim health-rel drug geograph perspect close half
compani sale gener unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
merck post strong support robust keytruda
growth fade gener pressur apr
merck report first-quart result slightli ahead
expect expect chang fair
valu estim base minor out-performance
continu see compani larg fairli valu
strong outlook merck immuno oncolog platform
larg factor stock believ strong cancer
platform combin solid portfolio brand
quarter total sale increas oper
buoy growth cancer drug keytruda offset
deceler gener competit cardiovascular drug
zetia vytorin well slight declin diabet drug
januvia janumet expect keytruda gain
slow key market non-smal cell lung cancer
nsclc becom satur keytruda use
close posit patient group continu
expect peak annual keytruda sale billion
support significantli usag nsclc outsid
 well new indic renal small cell lung
tripl neg breast cancer near term also beyond
keytruda expect addit growth human
papillomaviru vaccin gardasil post growth
quarter buoy growth china growth driver
continu drive solid overal top-lin growth
merck face less patent loss near term
top solid top-lin growth merck post
improv oper margin expect continu
partli driven high-margin contribut keytruda
gain price close per annual cours
treatment rel lower market cost keytruda
help drive expand margin next sever
year project oper margin expand
basi point next three year
pipelin front merck make stride
believ breadth late-stag pipelin need
expand beyond new indic expect keytruda
remain skeptic merck next gener pneumococc
vaccin abl gain share
entrench posit howev early-stag data hiv
drug look promis believ drug
repres one import drug firm
maintain fair valu estim per share
continu expect steadi long-term
growth partli driven solid outlook cancer drug
keytruda lesser extent strong outlook hpv
vaccin gardasil larg intern market keytruda
key merck valuat expect leader
immuno-oncolog market expect drug
reach peak sale billion larg base strong
efficaci sever cancer type includ lung head
neck melanoma sever cancer indic
look entir compani next five year
expect merck post annual top-lin growth
new drug offset drug lost gener competit
potenti game changer growth rate includ
compani pipelin immuno-oncolog drug move
quickli clinic develop merck still face
gener competit older drug remicad zetia
vytorin next year howev believ
pipelin drug growth exist drug off-set
near-term gener headwind overal expect larg
stabl margin near term minor
improv specialty-ori drug launch
carri strong price power need less market support
maintain uncertainti rate merck
medium overal larg base cash flow
divers inelast product portfolio rate merck
uncertainti medium view merck uncertainti
medium rather low due increas import
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
gener drug compani enorm cash
flow support power salesforc sell
current market drug also serv deterr
develop drug compani seek launch compet
opportun extern develop drug cash flow
also put compani rare posit support
approxim million need averag
bring new drug market power
merck research laboratori still hold
vast databas knowledg help compani
maintain leadership posit drug discoveri
develop also compani entrench
immuno-oncolog area strengthen
merck competit posit drug carri
strong price power area unmet medic need lastli
merck strong entrench vaccin add layer
competit protect intellectu properti cost
advantag compani large-scal product
face deterior moat trend past merck
competit advantag stabil patent protect
still shield major drug competit
compani develop enough new drug off-set
eventu patent loss pipelin side merck made
strateg shift acceler move focu
unmet medic need specialti care area
debilit lethal diseas strateg shift help
increas product fight back
follow three neg trend first post-vioxx era
food drug administr grown increasingli
risk-sensit primary-car diseas tend approv
safe drug drug highli need area
cancer second insur compani steadili
reduc coverag follow-on drug forc drug firm
push true innov reduc power
distribut network lastli govern
keytruda look well posit partli reduc
merck product divers cash flow scenario
analysi assum base-cas fair valu estim
bull case probabl bear case
base case scenario analysi show modest
varianc henc medium uncertainti rate
key factor affect scenario analysi includ
degre success brand drug pipelin along
magnitud market pressur current market
drug within portfolio import driver
valuat keytruda cancer close quarter
sale come keytruda impact competit
new clinic data significantli affect import drug
merck
patent economi scale power intellectu
base buoy merck busi keep well shield
competit bedrock merck wide moat
patent protect continu keep competitor
bay compani strive introduc next
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
develop market increasingli use compar
effect program aggress push
price negoti respons challeng merck
strateg focu toward unmet medic need
increas probabl success regulatori agenc
support stronger price power payer fewer
altern exist treatment area
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
okeytruda look best posit immuno-
advantag import indic first-lin non-
landscap buoy
omerck key drug januvia look potenti safer
diabet drug follow-on combin
drug drive futur growth
omerck support strong dividend yield look
secur base wide diversifi portfolio drug
ooutsid immuno oncolog merck need increas
number late-stag pipelin drug
owhil major patent loss behind
compani firm face gener competit
januvia potenti earli
oadvanc oncolog happen quickli
could caus disrupt merck lead growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
merck remain solid financi foot compani
close debt/capit strong cash flow
expect next sever year
strengthen balanc sheet howev merck signal
strong willing make acquisit histor
tend make sever bolt-on acquisit year
given merck made major acquisit sinc
schering-plough deal expect make
larger acquisit next two three year beyond
acquisit expect steadi futur dividend support
pay-out ratio close rel adjust
merck near-term risk larg center market accept
new drug like pharmaceut compani merck
face regulatori risk fda product delay
nonapprov could hurt stock also grow power
manag care price-sensit
addit merck face remain legal risk
vioxx major plaintiff particip
billion settlement holdout could ring major
addit settlement also litig risk remain
patient took one-tim blockbust fosamax
osteoporosi medicin link infrequ
seriou side effect lastli grow success
keytruda increas compani depend
drug growth could becom problemat new
therapi emerg quickli treat cancer howev
overal view merck uncertainti medium given
wide divers larg inelast drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mr kenneth frazier ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund incom fund amer
share
fund
share
fund
ken frazier took ceo dick clark begin
appoint chairman board late
clark near retir age view
new leader continu merck past strategi
red flag shift leadership approach frazier
part success strategi guid clark frazier
almost two decad experi merck across
major divis posit well lead
compani also deserv much credit
success handl vioxx litig held
merck gener counsel posit major
litig merck board pack current retir
ceo lead quid pro quo compens
top execut
rate compani stewardship standard merck
shown reason use capit purchas
schering-plough fair price brought sever
import pipelin product includ keytruda
allow cost-cut opportun hand
billion acquisit cubist seem like stretch
make valuat work especi announc
sooner-than-expect patent loss key drug cubicin
merck heavi fund past decad
produc mix result sever import new drug
also mani failur howev compani final
shift focu toward area specialti care away
primari care continu support
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
merck keytruda post solid data renal cancer
open anoth growth avenu drug feb
merck report posit keytruda data combin
inlyta first-lin renal cancer open anoth
growth opportun drug outsid lung cancer
lung cancer remain biggest opportun
keytruda project renal cancer drug sale immuno
oncolog drug reach billion annual
howev expect major chang fair
valu estim merck bristol hold compet
renal cancer opdivo plu yervoy
nevertheless continu strong data multipl cancer
reinforc strength keytruda across multipl
indic provid merck strong pillar support
wide moat
project data drive close market share
merck keytruda renal cancer detail data
present genitourinari cancer
symposium summari overal surviv data
improv look like strongest data report
renal cancer far howev rate side effect
grade partli concern given lethal natur
diseas expect keytruda gain market share
like stronger gain patient low
express opdivo lack competit data expect
bristol opdivo plu yervoy retain close remaind
first-lin renal cancer market despit slightli wors
surviv benefit overal surviv benefit
benefit patient combin better
side-effect profil patient side effect
grade first-mov advantag approv
april also opdivo gain approv later line
renal cancer sever year ago set strong
entrench physician commun also pfizer
partner merck kgaa roch look gain approv
treat renal cancer immuno oncolog drug
limit data regimen look
detail look immuno oncolog
landscap pleas see annual pipelin report annual
drug pipelin report moat remain secur innov
counter price gener headwind
led keytruda gardasil merck post strong fourth
merck report strong fourth-quart result ahead
expect consensu plan
slightli rais fair valu estim base strong
result particular sale cancer drug keytruda hpv
vaccin gardasil ran ahead project expect
product post continu gain driven expand
indic well entrench intern
market overal strong growth merck portfolio
along grow pipelin reaffirm compani
quarter keytruda gardasil grew
respect help off-set competit pressur older
drug support overal sale growth rate
slightli higher annual rate expect merck
post next three year keytruda label
expans first-lin non-smal cell lung cancer nsclc
drive drug growth expect growth
indic intern drug use
combin chemotherapi start
doubl address patient group area
also gardasil recent launch china add
million women elig receiv vaccin
addit gener competit cardiovascular
drug zetia vytorin along brand competit
hepat drug zepati hurt growth quarter
expect headwind pressur declin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pipelin front merck make strong progress
believ import advanc year ahead
includ detail data keytruda first-lin renal cell
cancer studi small cell lung cancer
well phase data hiv drug phase
data pneumococc vaccin addit
recent breakthrough design fda
suggest vaccin may significantli stronger
clinic profil entrench prevnar
complet review merck pipelin current
market portfolio pleas see healthcar observ
annual drug pipelin report moat remain secur
innov counter price gener headwind
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
